Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb (BMY) is pitched as the better long-term buy versus Johnson & Johnson (JNJ), with BMY trading at a much lower forward P/E (9.1 vs 22.0) and P/S (2.4 vs 6.5). BMY posted fiscal 2025 revenue near $48.2B (down ~0.2%) and net income of about $7.1B (net margin ~14.6%), alongside free cash flow of ~$12.8B and a higher debt-to-equity of ~2.6 (vs J&J’s ~0.6). The bullish case for BMY is framed around its pipeline and “Growth Portfolio” despite IRA-driven pricing pressure (e.g., Eliquis) and loss of exclusivity (e.g., Revlimid), while J&J is weighed down by talc litigation (60,000 unresolved U.S. cases) and biosimilar competition (e.g., Stelara), plus orthopedics separation execution risk.

Analysis

The market is likely to treat this as a slow-burn relative-value setup, not an event-driven catalyst. BMY’s low multiple only works if the Street starts believing its cash earnings can outgrow the patent/price-pressure drag; otherwise the discount is just the correct price for a shrinking franchise with leverage. JNJ’s premium is anchored less in growth than in balance-sheet durability and capital return capacity, so the burden of proof for a rerating is lower than the article implies.

Second-order, the cleaner read is that BMY competes for investor capital with other quality pharma names that have better earnings visibility, especially MRK and AMGN. If BMY underdelivers on pipeline conversion, the capital will likely rotate to those names rather than into JNJ; if JNJ’s legal noise persists, it mainly caps multiple expansion rather than forcing a fundamental deterioration unless reserves rise materially. The MedTech separation matters more as a volatility event than an earnings event: it can unlock sum-of-parts value, but it also creates index/rebalancing flows and short-term technical dislocation.

The contrarian miss is that JNJ may be less broken than the narrative suggests, while BMY may be cheaper for a reason that lasts 12-24 months. Consensus is overweight headline litigation fatigue and underweight the possibility that BMY’s replacement cycle disappoints before the valuation gap closes. What would falsify that view: a stable-to-rising BMY earnings guide with credible pipeline monetization, or, on the other side, a larger JNJ legal reserve / adverse ruling that changes capital allocation math rather than just sentiment.

Key Decisions for Investors

• Initiate a small 3-6 month long BMY / short JNJ pair only if you want to express relative litigation-vs.-valuation dispersion; keep sizing modest because the trade lacks a near-term catalyst and can bleed if both names de-risk together.
• Do not short JNJ outright here; the balance sheet and free-cash-flow base should absorb headline noise unless legal reserves step-up materially. Reassess only if there is a reserve increase or adverse ruling that meaningfully changes buyback capacity.
• Use BMY as a watchlist long into the next earnings/guidance print: buy only if management shows stable FY26 earnings and pipeline conversion. If guidance slips, the value case is likely a trap and should be abandoned quickly.
• For higher-quality exposure, prefer MRK or AMGN over either name on a 6-18 month horizon; they offer cleaner earnings visibility and are less dependent on multiple compression/recovery to work.